Of course, the interest in SIRFLOX could be either - it works;...

Of course, the interest in SIRFLOX could be either

- it works; or

- it doesn't work (or doesn't work in certain circumstances)

Both outcomes, positive and negative, are of interest to oncology.

I looked up one of the other oral presentations and it seems to be based on a study showing greater survival for a particular treatment on  "mismatch repair–deficient proximal tumors" but not for "mismatch repair–deficient distal tumors". In other words, giving oncologists information about what treatment works - and does not work - in different situations or for different types of cancer. Very useful information to guide an oncologist; knowing that a treatment doesn't work is pretty important.

You will also see that a lot of the presentations discuss FOLFOX, which is the standard treatment (SIRFLOX is FOLFOX + SIRT); obviously there is massive interest in whether SIRT helps.

All in all....I don't think anything can necessarily be read into it other than, whatever the outcome, its in an area of interest and benefit to oncologists.

The liver cancer results from the Ph III might suggest something useful thought.